Patrick Burnett - 15 Dec 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Reporting Person's Title: Executive Vice President and Chief Medical Officer
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett
Issuer symbol
ARQT
Transactions as of
15 Dec 2025
Net transactions value
-$290,991
Form type
4
Filing time
17 Dec 2025, 17:53:56 UTC
Previous filing
10 Nov 2025
Next filing
02 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Burnett Patrick Reporting Person's Title: Executive Vice President and Chief Medical Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE /s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett 17 Dec 2025 0001741987

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise $41,860 +11,500 +12% $3.64 109,807 15 Dec 2025 Direct F1, F2
transaction ARQT Common Stock Sale $332,851 -11,500 -10% $28.94 98,307 15 Dec 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Options Exercise $0 -11,500 -7.4% $0.000000 143,750 15 Dec 2025 Common Stock 11,500 $3.64 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.
F2 Due to a scrivener's error on the Reporting Person's Form 4 filed on November 5, 2025, the number of shares of common stock beneficially owned by the Reporting Person was inadvertently overstated by 18 shares. The corrected number of shares beneficially owned is reflected in this Form 4.
F3 The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.61 to $29.20, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Remarks:

Reporting Person's Title: Executive Vice President and Chief Medical Officer